Sarepta Therapeutics Inc [NASDAQ: SRPT] price plunged by -27.44 percent to reach at -$27.81.
The one-year SRPT stock forecast points to a potential upside of 57.9. The average equity rating for SRPT stock is currently 1.46, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Sarepta Therapeutics Inc [SRPT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SRPT shares is $174.68 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SRPT stock is a recommendation set at 1.46. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Deutsche Bank have made an estimate for Sarepta Therapeutics Inc shares, keeping their opinion on the stock as Hold, with their previous recommendation back on February 11, 2025. While these analysts kept the previous recommendation, Needham dropped their target price from $205 to $202. The new note on the price target was released on November 27, 2024, representing the official price target for Sarepta Therapeutics Inc stock. Previously, the target price had yet another raise to $80, while H.C. Wainwright analysts kept a Sell rating on SRPT stock. On November 07, 2024, analysts increased their price target for SRPT shares from 152 to 167.
The Average True Range (ATR) for Sarepta Therapeutics Inc is set at 5.86, with the Price to Sales ratio for SRPT stock in the period of the last 12 months amounting to 3.75. The Price to Book ratio for the last quarter was 4.66, with the Price to Cash per share for the same quarter was set at 13.96.
SRPT Stock Performance Analysis:
Sarepta Therapeutics Inc [SRPT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -26.98. With this latest performance, SRPT shares dropped by -31.88% in over the last four-week period, additionally sinking by -41.00% over the last 6 months – not to mention a drop of -40.58% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SRPT stock in for the last two-week period is set at 21.75, with the RSI for the last a single of trading hit 17.99, and the three-weeks RSI is set at 24.97 for Sarepta Therapeutics Inc [SRPT]. The present Moving Average for the last 50 days of trading for this stock 110.71, while it was recorded at 94.04 for the last single week of trading, and 125.67 for the last 200 days.
Insight into Sarepta Therapeutics Inc Fundamentals:
Sarepta Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.18 and a Current Ratio set at 4.20.
SRPT Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SRPT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sarepta Therapeutics Inc go to 93.33%.
Sarepta Therapeutics Inc [SRPT] Institutonal Ownership Details
There are presently around $92.27%, or 96.52%% of SRPT stock, in the hands of institutional investors. The top three institutional holders of SRPT stocks are: BLACKROCK INC. with ownership of 10.32 million shares, which is approximately 10.9845%. VANGUARD GROUP INC, holding 9.04 million shares of the stock with an approximate value of $$1.43 billion in SRPT stocks shares; and VANGUARD GROUP INC, currently with $$682.69 million in SRPT stock with ownership which is approximately 4.5666%.
